HC Wainwright & Co. Reiterates Buy on PolyPid, Maintains $13 Price Target
PolyPid: 3 Key Takeaways for Long-Term Investors
PolyPid Ltd. Q3 2026 Earnings Call Summary
PolyPid (PYPD) Q3 2026 Earnings Call Transcript
PolyPid Ltd (PYPD) Q3 2026 Earnings Call Highlights: D-PLEX100 Nears FDA Decision as Azurity ...
PolyPid Ltd. (PYPD) Q3 2026 Earnings Call Transcript
What PolyPid (PYPD) Said on Its Q3 Earnings Call
PolyPid Provides Corporate Update and Reports Third Quarter 2026 Financial Results
PolyPid Q3 2026 Earnings Call Transcript
PolyPid Q3 EPS $(0.24) Misses $0.06 Estimate
PolyPid: Strong Phase 3 Data Support A Buy Ahead Of November's FDA Decision
PolyPid Ltd. (PYPD) Analyst/Investor Day - Slideshow
PolyPid to Report Third Quarter 2026 Financial Results and Operational Highlights on November 11, 2026
PolyPid Targets 2027 D-PLEX100 Launch, Unveils Diabetic Foot Infection Program
PolyPid Ltd. (PYPD) Analyst/Investor Day Transcript
PolyPid Unveils Expanded Pipeline Strategy, Introducing PD01B, a New Kynatrix™ Based Product Candidate for the Treatment of Diabetic Foot Infections
Oppenheimer Initiates Coverage On PolyPid with Outperform Rating, Announces Price Target of $10
PolyPid to Present D-PLEX₁₀₀ Microbiology Data at IDWeek 2026
PolyPid to Host Virtual Investor Day on Wednesday, October 28, 2026
PolyPid Nears FDA Decision for D-PLEX100 After Strong Phase III Data
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.